UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 252

Sortiert nach

Tumor-infiltrating dendritic cells in cancer pathogenesis

The Journal of immunology (1950), 2015-04, Vol.194 (7), p.2985-2991

2015

Link zum Volltext

Verfügbarkeit prüfen

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Journal of hematology and oncology, 2018-03, Vol.11 (1), p.39-39, Article 39

2018

Link zum Volltext

Verfügbarkeit prüfen

Resistance to Trastuzumab

Cancers, 2022-10, Vol.14 (20), p.5115

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer immunotherapy beyond immune checkpoint inhibitors

Journal of hematology and oncology, 2018-01, Vol.11 (1), p.8-25, Article 8

2018

Link zum Volltext

Verfügbarkeit prüfen

Rheumatoid arthritis and cardiovascular disease

The American heart journal, 2013-10, Vol.166 (4), p.622-628.e1

2013

Link zum Volltext

Verfügbarkeit prüfen

The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease

Scientific reports, 2016-08, Vol.6 (1), p.30751, Article 30751

2016

Link zum Volltext

Verfügbarkeit prüfen

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

Cancer research (Chicago, Ill.), 2017-12, Vol.77 (23), p.6667-6678

2017

Link zum Volltext

Verfügbarkeit prüfen

Downregulation of TAP1 and TAP2 in early stage breast cancer

PloS one, 2017-11, Vol.12 (11), p.e0187323-e0187323

2017

Link zum Volltext

Verfügbarkeit prüfen

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

Clinical cancer research, 2018-07, Vol.24 (13), p.3014-3025

2018

Link zum Volltext

Verfügbarkeit prüfen

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

Nature nanotechnology, 2017-08, Vol.12 (8), p.763-769

2017

Link zum Volltext

Verfügbarkeit prüfen

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer

PloS one, 2013-11, Vol.8 (11), p.e80063-e80063

2013

Link zum Volltext

Verfügbarkeit prüfen

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer

The Journal of immunology (1950), 2011-06, Vol.186 (12), p.6905-6913

2011

Link zum Volltext

Verfügbarkeit prüfen

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1), p.22-30

2015

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways

The Journal of immunology (1950), 2024-05, Vol.212 (9), p.1397

Knutson, Keith L

2024

Link zum Volltext

Verfügbarkeit prüfen

Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells

Cancer research (Chicago, Ill.), 2009-04, Vol.69 (7), p.2887-2895

2009

Link zum Volltext

Verfügbarkeit prüfen

Folate receptor alpha as a tumor target in epithelial ovarian cancer

Gynecologic oncology, 2008-03, Vol.108 (3), p.619-626

2008

Link zum Volltext

Verfügbarkeit prüfen

Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer

Journal of translational medicine, 2013-01, Vol.11 (1), p.20-20, Article 20

2013

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Journal for immunotherapy of cancer, 2018-11, Vol.6 (1), p.129-129, Article 129

2018

Link zum Volltext

Verfügbarkeit prüfen

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients

Frontiers in immunology, 2023-07, Vol.14, p.1224702-1224702

2023

Link zum Volltext

Verfügbarkeit prüfen

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

Clinical cancer research, 2007-09, Vol.13 (17), p.5133-5143

2007

Link zum Volltext

Verfügbarkeit prüfen

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

Oncoimmunology, 2020-01, Vol.9 (1), p.1744947-1744947

2020

Link zum Volltext

Verfügbarkeit prüfen

A pilot trial of intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis

Scientific reports, 2021-03, Vol.11 (1), p.4946-4946, Article 4946

2021

Link zum Volltext

Verfügbarkeit prüfen

Functional folate receptor alpha is elevated in the blood of ovarian cancer patients

PloS one, 2009-07, Vol.4 (7), p.e6292-e6292

2009

Link zum Volltext

Verfügbarkeit prüfen

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

Journal of clinical oncology, 2002-06, Vol.20 (11), p.2624-2632

2002

Link zum Volltext

Verfügbarkeit prüfen

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Breast cancer research : BCR, 2018-06, Vol.20 (1), p.52-9, Article 52

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 252

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(234)

Publikationsform

Sprache

Englisch
(252)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Tumor-infiltrating dendritic cells in cancer pathogenesis

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Resistance to Trastuzumab

Cancer immunotherapy beyond immune checkpoint inhibitors

Rheumatoid arthritis and cardiovascular disease

The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

Downregulation of TAP1 and TAP2 in early stage breast cancer

Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer

Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer

Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

Regulation of Tumor Dendritic Cells by Programmed Cell Death 1 Pathways

Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells

Folate receptor alpha as a tumor target in epithelial ovarian cancer

Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients

Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

A pilot trial of intravital microscopy in the study of the tumor vasculature of patients with peritoneal carcinomatosis

Functional folate receptor alpha is elevated in the blood of ovarian cancer patients

Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide–Based Vaccines

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

Suchergebnisse filtern